Singapore markets closed
Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,307.01 -14.40 (-0.27%) Dow
39,671.04 -201.95 (-0.51%) Nasdaq
16,801.54 -31.08 (-0.18%) Bitcoin USD
69,773.33 -383.67 (-0.55%) CMC Crypto 200
1,500.31 -2.35 (-0.16%)
ALLO Aug 2024 5.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:57PM EDT. Market open.
| Previous close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 5.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.1500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.1k |
ZacksAllogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
- GuruFocus.com
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Exploring Allogene's Q1 performance, strategic initiatives in oncology, and financial maneuvers amidst a challenging landscape.
ZacksAllogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 0% and 47.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.